Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

You inject the drug into your stomach ... a single-dose vial rather than as an auto-injector pen, also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock Two ... compounds similar to the compounds in Mounjaro, Wegovy and Zepbound may work especially well for people with the "hungry ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible ...

Doses and their portions can be controlled with injection pens; you will receive instructions ... Tirzepatide, sold as Mounjaro and Zepbound, is another GLP-1 agonist and a GIP agonist, too.